

Date 04/04/2025
Your Ref
Our Ref 9851

Enquiries to Richard Mutch
Extension 35687
Direct Line 0131 465 5687
loth.freedomofinformation@nhs.scot
richard.mutch@nhs.scot

Dear

FREEDOM OF INFORMATION – UROTHELIAL CANCER

I write in response to your request for information in relation to Urothelial cancer prescribing.

Question:

1. Do you treat patients for Urothelial cancer (Yes or No)? If No, where do you refer patients for treatment

Answer:

Yes.

Question:

2. How many patients were treated for Urothelial cancer (any stage) in the past 3 months with the following treatments:

Atezolizumab (Tecentriq)
Avelumab (Bavencio)
Carboplatin single agent or in any other combination
Carboplatin with Gemcitabine
Carboplatin with Gemcitabine + Avelumab (Bavencio)
Carboplatin with Paclitaxel
Cisplatin single agent or in any other combination
Cisplatin with Gemcitabine
Cisplatin with Gemcitabine + Nivolumab (Opdivo)
Cisplatin with Gemcitabine + Avelumab (Bavencio)
Enfortumab Vedotin + Pembrolizumab (Padcev + Keytruda)
Nivolumab (Opdivo)
Pembrolizumab (Keytruda)
Other active systemic anti-cancer therapy
Palliative care only
Erdafitinib

Headquarters
Mainpoint
102 West Port
Edinburgh EH3 9DN

Chair Professor John Connaghan CBE
Chief Executive Professor Caroline Hiscox
Lothian NHS Board is the common name of Lothian Health Board

Answer:

2a	Atezolizumab (Tecentriq)	Nil
2b	Avelumab (Bavencio)	5<
2c	Carboplatin single agent or in any other combination	Nil
2d	Carboplatin with Gemcitabine	Nil
2e	Carboplatin with Gemcitabine + Avelumab (Bavencio)	Nil
2f	Carboplatin with Paclitaxel	Nil
2g	Cisplatin single agent or in any other combination	Nil
2h	Cisplatin with Gemcitabine	Nil
2i	Cisplatin with Gemcitabine + Nivolumab (Opdivo)	Nil
2j	Cisplatin with Gemcitabine + Avelumab (Bavencio)	Nil
2k	Enfortumab Vedotin + Pembrolizumab (Padcev + Keytruda)	Nil
2l	Nivolumab (Opdivo)	5<
2m	Pembrolizumab (Keytruda)	5<
2n	Other active systemic anti-cancer therapy	Nil
2o	Palliative care only	N-A
2p	Erdafitinib	Nil

Question:

3. How many patients have been treated for metastatic Urothelial cancer in the past 3 months with the following systemic anti-cancer therapies:

Carboplatin single agent or in any other combination
 Carboplatin with Gemcitabine
 Carboplatin with Gemcitabine + Avelumab (Bavencio)
 Carboplatin with Paclitaxel
 Cisplatin single agent or in any other combination
 Cisplatin with Gemcitabine
 Cisplatin with Gemcitabine + Avelumab (Bavencio)

Answer:

3a	Carboplatin single agent or in any other combination	Nil
3b	Carboplatin with Gemcitabine	Nil
3c	Carboplatin with Gemcitabine + Avelumab (Bavencio)	Nil
3d	Carboplatin with Paclitaxel	Nil
3e	Cisplatin single agent or in any other combination	Nil
3f	Cisplatin with Gemcitabine	Nil
3g	Cisplatin with Gemcitabine + Avelumab (Bavencio)	Nil

Question:

4. Does your trust participate in any ongoing clinical trials for the treatment of urothelial cancer? If so, can you please provide the name of each trial along with the number of patients taking part?

Answer:

Full Title	Recruited
DISCUS, A randomised phase II study comparing 3 vs 6 cycles of platinum-based chemotherapy prior to maintenance avelumab in advanced urothelial cancer.	7
ModiFY, A Phase 1/2, Multicentre, Open-Label Study of Modi-1 in Patients with Breast, Head and Neck, Ovarian, or Renal Cancer.	5<

To protect the identity of the individuals involved any figure of 5 or less has not been shown in the tables above. Since we do not have their consent to release this data from their records, the information is exempt under section 38(1)(b) of the Freedom of Information (Scotland) Act i.e. to provide it would breach the Data Protection Act (2018).

I hope the information provided helps with your request.

If you are unhappy with our response to your request, you do have the right to request us to review it. Your request should be made within 40 working days of receipt of this letter, and we will reply within 20 working days of receipt. If our decision is unchanged following a review and you remain dissatisfied with this, you then have the right to make a formal complaint to the Scottish Information Commissioner within 6 months of receipt of our review response. You can do this by using the Scottish Information Commissioner's Office online appeals service at www.itspublicknowledge.info/Appeal. If you remain dissatisfied with the Commissioner's response you then have the option to appeal to the Court of Session on a point of law.

If you require a review of our decision to be carried out, please write to the FOI Reviewer at the email address at the head of this letter. The review will be undertaken by a Reviewer who was not involved in the original decision-making process.

FOI responses (subject to redaction of personal information) may appear on NHS Lothian's Freedom of Information website at: <https://org.nhslothian.scot/FOI/Pages/default.aspx>

Yours sincerely

ALISON MACDONALD
Executive Director, Nursing
 Cc: Chief Executive